Volume | 1,200,078 |
|
|||||
News | - | ||||||
Day High | 9.35 | Low High |
|||||
Day Low | 8.79 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Mind Medicine MindMed Inc | MNMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.86 | 8.79 | 9.35 | 8.87 | 8.69 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,330 | 1,200,078 | $ 9.09 | $ 10,910,139 | - | 2.41 - 12.22 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:51:54 | 67 | $ 8.94 | USD |
Mind Medicine MindMed (MNMD) Options Flow Summary
Mind Medicine MindMed Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.89M | 41.33M | - | 0 | -95.73M | -2.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mind Medicine MindMed News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.59 | 10.0489 | 8.26 | 9.05 | 1,130,704 | -0.64 | -6.67% |
1 Month | 10.51 | 12.22 | 8.26 | 10.27 | 1,842,622 | -1.56 | -14.84% |
3 Months | 4.00 | 12.22 | 3.795 | 8.78 | 2,374,276 | 4.95 | 123.75% |
6 Months | 2.62 | 12.22 | 2.41 | 7.63 | 1,404,542 | 6.33 | 241.60% |
1 Year | 3.95 | 12.22 | 2.41 | 6.71 | 935,224 | 5.00 | 126.58% |
3 Years | 85.3005 | 86.55 | 2.12 | 27.84 | 3,274,490 | -76.35 | -89.51% |
5 Years | 85.3005 | 86.55 | 2.12 | 27.84 | 3,274,490 | -76.35 | -89.51% |
Mind Medicine MindMed Description
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. |